Figure 2.

LSM change from baseline and LSM treatment differences in IBDQ domain scores at (A) Week 12 and Week 52 in ELEVATE UC 52 and (B) Week 12 in ELEVATE UC 12. Estimates are from a mixed-effect model with repeated measures (ELEVATE UC 52) and an analysis of covariance model (ELEVATE UC 12) for change from baseline with a covariate for baseline score, and factors for naive-to-biologic/JAKi therapy at study entry (Yes/No), baseline corticosteroid use (Yes/No), baseline disease activity (MMS 4-6 or 7-9), and treatment. Covariates for visit and treatment-by-visit interaction were also included in the mixed-effect model with repeated measures. Abbreviations: Δ, LSM difference between treatments; IBDQ, Inflammatory Bowel Disease Questionnaire; JAKi, Janus kinase inhibitor; LSM, least squares mean; MMS, modified Mayo score; QD, once daily; UC, ulcerative colitis.